Previous 10 | Next 10 |
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate...
Applied Therapeutics ( NASDAQ: APLT ) reported data from an ongoing phase 3 trial of oral AT-007 in 50 patients aged 16 years to 55 years with Sorbitol Dehydrogenase (SORD) Deficiency. An interim analysis of the study, dubbed INSPIRE, showed that AT-007 reduced sorbitol leve...
The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16-55 in the US and Europe AT-007 reduced sorbitol by a mean of 52%, or approximately 16,00...
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present virt...
Best Penny Stocks To Buy? 7 To Watch With Big Headlines In January 2023 Are you ready to get the ball rolling with penny stocks in 2023? You’re not alone, but unlike other years, chances are we’ll see much more volatility in the stock market. Heightened concerns over inflation, ...
Applied Therapeutics ( NASDAQ: APLT ) added ~19% pre-market Wednesday after announcing a partnership with U.K.-based pharmaceutical company Advanz Pharma to commercialize its lead candidate AT-007 (govorestat) in Europe. Per the terms, Advanz Pharma will receive the exclusive comm...
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency Applied Therapeutics will receive milestone payments of over €130 million and 20% royalty payments on net s...
Applied Therapeutics press release ( NASDAQ: APLT ): Q3 GAAP EPS of -$0.40 beats by $0.12 . Cash and cash equivalents and short-term investments totaled $47.4 million as of September 30, 2022, compared with $80.8 million at December 31, 2021. For further details ...
NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...
Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodeling Baseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as ...
News, Short Squeeze, Breakout and More Instantly...
Applied Therapeutics Inc. Company Name:
APLT Stock Symbol:
NYSE Market:
Applied Therapeutics Inc. Website:
2024-07-27 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was adde...
2024-06-11 10:45:04 ET Palo Alto Networks Inc (PANW) PANW is trading UP for the last 5 days, and it at trading at $313.28 with volume of 858,188 and a one day change of $4.23 (1.37%). Palo Alto Networks Inc has a 52-week low of 201.17 and a 52-week high of $380.84. The business's 50...